Next Generation CAR-TCR Summit

Memo

As the CAR-T field continues to explode with new companies, investment, and clinical collaborations, it's more important than ever to stay ahead of the curve. Stakeholders across oncology are now turning to next generation developments and innovations to create the therapies of tomorrow.That's why CAR-TCR Europe has evolved into the Next Generation CAR-TCR Summit: your definitive platform focused on the 2.0, next generation innovations in cell therapies.Join innovators from large pharma, biotech, academia and regulatory boards to hear insights into:Novel In-Vivo Delivery | Innovations in Gene, Base and Prime Editing | Novel Discovery Platforms | Overcoming the Hostile Tumour Microenvironment | Improving Persistence and Durability for Greater Clinical Outcomes | And More!Whether you are developing novel constructs, new clinical trial strategies or innovative manufacturing approaches for large scale production, this multi-tracked meeting can support your whole team and provide the tools needed to advance your own pipeline towards clinical and commercial success.URLs:Tickets: https://go.evvnt.com/935698-2?pid=5569Brochure: https://go.evvnt.com/935698-3?pid=5569Prices:Attend in Person - Drug Developer - Conference + Workshop Day: GBP 3796.0,Attend in Person - Drug Developer - Conference + Bootcamp Day: GBP 3796.0,Attend in Person - Drug Developer - Conference Only: GBP 2599.0,Attend Virtually - Drug Developer - Conference + Bootcamp Day: GBP 2746.0,Attend Virtually - Drug Developer - Conference Only: GBP 1999.0Speakers: Leah Sibener Co-Founder, Head of Therapeutic Discovery 3T Biosciences, Blake Aftab Chief Scientific Officer Adicet Bio, Jak Knowles Chief Executive Officer Affini-T Therapeutics, Eric Von Hofe Chief Executive Officer AffyImmune, Reagan Jarvis Chief Executive Officer Anocca, Sven Kili Chief Executive Officer Antion Biosciences, Christopher R. Heery Chief Medical Officer Arcellx, Jakob Dupont Executive Vice President, Head of Global Research and Development Atara Biotherapeutics, Pascal Touchon President and Chief Executive Officer Atara Biotherapeutics, Benjamin Rengstl Director Immunoreceptor Therapy and Medical Expert Clinical Development BioNTech Cell and Gene Therapies and BioNTech SE, Haig Aghajanian Vice President of Research Capstan Therapeutics, Rudy Gonzalez Executive Director of Stem Cell Therapeutics Caribou Biosciences, Steve Kanner Chief Scientific Officer Caribou Biosciences, Michael Kchlinsky Co-Founder and Senior Vice President, Research Carisma Therapeutics, Hong Ma Senior Vice President, Clinical Development CARsgen Therapeutics, Richard Boyd Chief Scientific Officer Cartherics, Marco Rotondi Project Leader - Process Development Cellectis, Yihong Yao Chief Scientific Officer CBMG, Remus Veza Chief Medical Officer CERo Therapeutics, Emilie Gauthy Research and Development Manager, CMC and Process Development Celyad Oncology, John Rossi Senior Vice President, Translational Medicines and Research CERo Therapeutics, Stanley Frankel Chief Medical Officer Cytovia, Mubin Tarannum Post-Doctoral Researcher Dana-Farber Cancer Institute , Sylvain Simon Postdoctoral Fellow Fred Hutchinson Cancer Research Center , Christopher Baldwin Chain Director, Cell and Gene Therapy GSK, Maria Castella Research Associate, Immunotherapy Unit Hospital Clinic de Barcelona, Cedrik Britten Chief Medical Officer Immatics, Ali Mohamed Vice President of CMC Immatics, Hemant Dhamne Head Process Development and Manufacturing Immuneel Therapeutics, Lawrence Lamb Chief Scientific Officer IN8bio, William Ho Chief Executive Officer IN8bio, Cecile Bauche Chief Scientific Officer Ixaka, Maurizio Chiriva Internati President, Chief Executive Officer, Chairman and Founder Kiromic BioPharma, Adrian Bot Vice President and Global Head of Translational Medicine, and Research Site Head Kite Pharma, John Maher Chief Scientific Officer Leucid Bio, Rogier Reijmers Principal Scientist Lumicks, Tina Albertson Chief Medical Officer, Head of Development Lyell Immunopharma, Mythili Koneru Chief Medical Officer Marker Therapeutics , Lucia Mori Founding Chief Scientific Officer Matterhorn Biosciences, Maja Buerdek Director Translational Medicine Medigene, Dolores J. Schendel Chief Executive Officer and Chief Scientific Officer Medigene, Melanie Rietenbach Global Product Manager Immunology Engineered Cells Miltenyi, Laura Pierce Biomedical Engineer NIST, Chris Bond Senior Vice President Preclinical and Translational Sciences Notch Therapeutics, Emily Titus Vice President, Process Sciences Notch Therapeutics, Dian Kortleve Scientist Pan Cancer T, Rajiv Khanna Senior Scientist, Head, Department of Immunology QIMR Berghofer Medical Research Institute, Marc Martinez-Llordella Founder and Vice President Biology Quell Therapeutics, Hinrich Abken Professor RCI Regensburg Center for Interventional Immunology, Giulia Casorati Head of Experimental Immunology Unit San Raffaele Scientific Institute, Terry Fry Senior Vice President, Head of T-Cell Therapeutics Sana Biotechnology, Geoff Hodge CEO SOTIO US, Peggy Sotiropoulo Chief Scientific Officer T-knife Therapeutics, Peter Olagunju Chief Technical Officer TCR2 Therapeutics, Marko Radic Associate Professor The University of Tennessee Health Science Center , Vijay Reddy Peddareddigari Chief Development Officer Tmunity Therapeutics, Scott Kitchen Director and Associate Professor - Medicine UCLA, David Fontana Chief Business and Strategy Officer Umoja BioPharma, Samantha O'Hara Allogeneic Research Lead Umoja BioPharma, Elie Haddad Professor, Department of Pediatrics University of Montreal, Roddy O'Connor Research Assistant Professor, Center for Cellular Immunotherapies UPenn School of Medicine, Jan DavidsonMoncada Chief Medical Officer Wugen, Namir Hassan Chief Executive Officer Zelluna ImmunotherapyDate and Time: On Tuesday February 22, 2022 at 9:00 am (ends Thursday February 24, 2022 at 5:00 pm)Venue Details: Novotel London West, 1 Shortlands, London, England, W6 8DR, United Kingdom